London
· Delayed Price · Currency is GBP · Price in EUR Evotec SE Company Description
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.
It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, fibrosis, immunology, pain and inflammation, infectious, kidney, liver, rare, respiratory, fibrotic and metabolic disease; central nervous system (CNS) and cardio-metabolic disorders; and animal and women health.
It has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore, as well as partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB; Bayer, Novo Nordisk, Eli Lilly, and Novartis company for kidney disease; and Sandoz, patient advocacy groups, and venture capital.
The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
| Country | Germany |
| Founded | 1993 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 4,740 |
| CEO | Christian Wojczewski |
Contact Details
Address: Essener Bogen 7 Hamburg, 22419 Germany | |
| Phone | 49 40 560 81 0 |
| Website | evotec.com |
Stock Details
| Ticker Symbol | 0IRF |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Paul Hitchin | Chief Financial Officer |
| Volker Braun | Executive Vice President and Head of Global Investor Relations and ESG |
| Dr. Christian Dargel | Executive Vice President Global Head of Legal and Compliance |
| Dr. Ian M. Hunneyball | Senior Vice President of Programme Management and Clinical Operations |
| Dr. David Hallet | Executive Vice President |
| Uwe Andag | Executive Vice President Head of Metabolic Diseases |
| Christiane Honisch | SVice President Head of Diagnostics |
| Claudia Karnbach | Executive Vice President, Global Head of Strategic Partnerships and Alliances and Site Head of Hamburg |
| Dr. Philip Boehme | Executive Vice President of Partnering and Transformation |
| Christian Buhlmann | Executive Vice President and Head of Global BD Development |